Penny L. Hubbard1, 2, Geoff J M Parker1, 2, Dave Singh3, Eva Bondesson4, 5, Lars E. Olsson4, Lars Wigstrm4, Simon S. Young6, Josephine H. Naish1, 2
1Imaging Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; 2The Biomedical Imaging Institute, The University of Manchester, Manchester, United Kingdom; 3Medicines Evaluation Unit, University Hospital Of South Manchester, The University of Manchester, Manchester, United Kingdom; 4AstraZeneca R& D, Sweden; 5Semcon Drug Development Consulting, Sweden; 6AstraZeneca R& D, United Kingdom
We present the results of a dynamic contrast-enhanced (DCE-) MRI study in subjects with Chronic Obstructive Pulmonary Disease (COPD) and age-matched healthy subjects. To our knowledge this is the first study to fit a pharmacokinetic model to an extended dynamic contrast-enhanced time series in this patient group. Fitting the extended Kety model revealed reductions in both the transfer coefficient (Ktrans) and pulmonary blood volume (vp) in severe COPD, but not moderate COPD. This is suggestive of reduced perfusion with increased disease severity.